Overview of lenvatinib as a targeted therapy for advanced hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide. Patients commonly present with advanced/unresectable HCC where several treatment options are not effective. In this review, the authors discuss the indications and usage of lenvatinib, a multikinase inhibitor, as first-lin...

Descripción completa

Detalles Bibliográficos
Autores principales: Rehman, Obaid, Jaferi, Urooj, Padda, Inderbir, Khehra, Nimrat, Atwal, Harshan, Mossabeh, Dina, Bhangu, Ranvir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2021
Materias:
Review Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527338/
https://www.ncbi.nlm.nih.gov/pubmed/34712825
http://dx.doi.org/10.5114/ceh.2021.109312

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527338/
https://www.ncbi.nlm.nih.gov/pubmed/34712825
http://dx.doi.org/10.5114/ceh.2021.109312

Ejemplares similares